Physician profile
Mary Remm
NPI 1295239093
$3,842.26
in general payments reported to CMS, 2019-2025
41 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $29.45 · 2023: $1,482 · 2024: $938 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607 · Travel and Lodging: $759 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,606.73 |
| Travel and Lodging | $759.06 |
| Education | $250.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $759.06 | 2023 | Proclaim |
| Pfizer INC. | $272.20 | 2023-2025 | |
| Beone Medicines USA, INC. | $202.09 | 2025 | Brukinsa, Tevimbra |
| Janssen Biotech, INC. | $185.06 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $163.80 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $141.03 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $140.98 | 2022-2025 | Enhertu, Vanflyta |
| Syndax Pharmaceuticals, INC. | $137.78 | 2025 | Revuforj |
| Incyte Corporation | $127.41 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Genzyme Corporation | $125.75 | 2023-2025 | |
| Exelixis INC. | $125.00 | 2023 | Cabometyx |
| Mirati Therapeutics, INC. | $124.94 | 2023 | Krazati |
| Astrazeneca Pharmaceuticals LP | $108.70 | 2023-2025 | Calquence, Enhertu, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $93.01 | 2024-2025 | Libtayo, Lynozyfic |
| Astellas Pharma US INC | $88.41 | 2023-2024 | Xospata, Vyloy |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Remm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.